Pharma BD Deal Intelligence
Distressed acquisition of a BLA-stage Fabry gene therapy
Full analysis, sources & comparables →Sangamo Form 8-K: Chapter 11 filing and asset sale agreements with Lilly and Astellas as stalking-horse bidders.
Sangamo enters asset sale agreement with Astellas for Fabry program ST-920 (isaralgagene civaparvovec); $25M at closing + up to $25M milestones; Astellas…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
As part of Sangamo Therapeutics' Chapter 11 filing, Astellas Pharma agreed to acquire Sangamo's Fabry disease gene therapy program isaralgagene civaparvovec (ST-920) for $25 million at closing plus up to $25 million in milestone payments. Astellas serves as the stalking-horse bidder under a Section 363 sale process subject to a court-supervised auction.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Astellas Pharma Inc. / Sangamo Therapeutics, Inc. (this deal) | 2026 | $50M | 63 |
| Astellas Pharma Inc. / Seagen Inc. | 2009 | $4.5B | 95 |
| Astellas Pharma Inc. / Ganymed Pharmaceuticals | 2016 | $1.4B | 81 |
| Astellas Pharma Inc. / Ogeda SA | 2017 | $850M | 59 |
| Astellas Pharma Inc. / Ocata Therapeutics, Inc. | 2015 | $379M | 41 |
| Astellas Pharma Inc. / Optimer Pharmaceuticals, Inc. | 2012 | $90M | 38 |
| Astellas Pharma Inc. / OSI Pharmaceuticals | 2010 | $4.0B | 33 |
← Browse all deals · How we score deals
More: 2026 deals · Astellas Pharma Inc. deals · Gene Therapy deals